52,239 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 52,239 shares of the company's stock, valued at approximately $2,016,000. Assenagon Asset Management S.A. owned approximately 0.09% of Protagonist Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC raised its position in shares of Protagonist Therapeutics by 749.2% in the third quarter. GAMMA Investing LLC now owns 552 shares of the company's stock worth $25,000 after buying an additional 487 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in Protagonist Therapeutics in the fourth quarter valued at approximately $38,000. Exchange Traded Concepts LLC bought a new position in shares of Protagonist Therapeutics in the 3rd quarter worth $43,000. CWM LLC lifted its holdings in shares of Protagonist Therapeutics by 910.3% during the 3rd quarter. CWM LLC now owns 1,273 shares of the company's stock worth $57,000 after acquiring an additional 1,147 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new position in Protagonist Therapeutics in the third quarter worth $69,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics Stock Performance

Shares of PTGX traded up $0.92 during mid-day trading on Thursday, reaching $37.80. The company had a trading volume of 525,034 shares, compared to its average volume of 595,110. Protagonist Therapeutics, Inc. has a 52 week low of $24.21 and a 52 week high of $48.89. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 14.21 and a beta of 2.23. The firm has a 50-day moving average price of $40.14 and a 200 day moving average price of $41.73.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The business had revenue of $4.68 million for the quarter, compared to the consensus estimate of $4.50 million. As a group, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PTGX. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, December 10th. TD Cowen upgraded shares of Protagonist Therapeutics to a "strong-buy" rating in a report on Wednesday, September 25th. The Goldman Sachs Group assumed coverage on shares of Protagonist Therapeutics in a report on Friday, December 6th. They set a "neutral" rating and a $47.00 price target for the company. BMO Capital Markets assumed coverage on shares of Protagonist Therapeutics in a report on Friday, December 6th. They issued an "outperform" rating and a $62.00 price target on the stock. Finally, Wedbush reissued an "outperform" rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $53.78.

Insider Activity

In other news, insider Arturo Md Molina sold 1,906 shares of the company's stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $40.98, for a total transaction of $78,107.88. Following the sale, the insider now directly owns 46,444 shares in the company, valued at approximately $1,903,275.12. This represents a 3.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suneel Gupta sold 103,437 shares of the business's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $46.04, for a total value of $4,762,239.48. Following the transaction, the insider now directly owns 256,174 shares in the company, valued at approximately $11,794,250.96. This represents a 28.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 209,863 shares of company stock valued at $9,689,847 in the last 90 days. Company insiders own 5.40% of the company's stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.